

Curriculum Vitae

Polly E. Parsons, M.D.
November 2014

Title: Professor of Medicine
E.L. Amidon Chair, Department of Medicine
University of Vermont
Burlington, Vermont 05401

Address: Fletcher 311
Fletcher Allen Health Care
111 Colchester Ave.
Burlington, Vermont 05401

Phone: 802-847-2550
Fax: 802-847-8194
E-mail: Polly.Parsons@uvmhealth.org

Department web site: <http://www.uvm.edu/medicine/medicine/>

EDUCATION

1971 - 1975	Radcliffe College, Harvard University A.B., Biology (Magna cum laude)
1975 - 1978	University of Arizona M.D., College of Medicine

POST-GRADUATE TRAINING

1978 - 1979	Intern, Internal Medicine University of Colorado Medical Center
1979 - 1981	Resident, Internal Medicine University of Colorado Medical Center
1981 - 1982	Research Fellow National Jewish Hospital and Research Center
1982 - 1985	Fellow, Pulmonary Medicine University of Colorado Health Sciences Center

ACADEMIC APPOINTMENTS

1985 - 1986	Instructor, Department of Medicine University of Colorado Health Sciences Center
1986 - 1992	Assistant Professor, Department of Medicine University of Colorado Health Sciences Center

1992 – 1999	Associate Professor (tenure track criteria) Department of Medicine University of Colorado Health Sciences Center
1999-2000	Professor (tenure track criteria), Department of Medicine University of Colorado Health Sciences Center
2000-present	Professor (with tenure), Department of Medicine University of Vermont
2000-2009	Director, Pulmonary and Critical Care Medicine University of Vermont
2005-2006	Interim Chair, Department of Medicine University of Vermont
2006- present	Chair, Department of Medicine University of Vermont

HOSPITAL APPOINTMENTS

1981 - 1985	Attending Physician, Ambulatory Care Denver Health Medical Center
1985 - 2000	Staff Physician, Department of Medicine Denver Health Medical Center
1985 - 1986	Medical Staff Physician National Jewish Center for Immunology and Respiratory Medicine
1986 - 2000	Special Faculty Member National Jewish Center for Immunology and Respiratory Medicine
1991 - 1993	Co-Director, Medical Intensive Care Unit Denver Health Medical Center
1993 – 2000	Director, MICU Denver Health Medical Center
2000-2009	Director, Pulmonary and Critical Care Medicine Unit Fletcher Allen Health Care
2000-2006	Chief of Critical Care Services Fletcher Allen Health Care

2000-2005	Director Pulmonary and Critical Care Medicine Fellowship Program Fletcher Allen Health Care/ University of Vermont College of Medicine
2000-2002	Medical Director, Respiratory Therapy Fletcher Allen Health Care
2005-2006	Interim Leader Medicine Health Care Service Fletcher Allen Health Care
2006-present	Leader, Medicine Health Care Service Fletcher Allen Health Care

BOARD CERTIFICATION

National Board of Medical Examiners - 1979
American Board of Internal Medicine - 1981
Subspecialty Examination, Pulmonary Disease - 1986
Subspecialty Examination in Critical Care Medicine-1989
Subspecialty Examination in Critical Care Medicine- 2005

LICENSURE

Colorado - #23641
Vermont- #42-0010040

RESEARCH GRANTS AND CONTRACTS

American Lung Association of Colorado Research Award, 7/85

Clinical Investigator Award, National Heart, Blood and Lung Institute, National Institutes of Health #KO8 HL01849, 8/86-7/91

NIH: NHBLI grant: RFA-HL87-01; 12/88 - 11/93

ARDS SCOR: JE Repine, Principal Investigator.

Project 6: The Pathogenesis of ARDS - **Polly E. Parsons**, Principal Investigator;

Core D: Clinical Core - **Polly E. Parsons**, Principal Investigator.

NIH: NHLBI grant: 2P50HL40:784-06; 12/93-11/98

SCOR in Acute Lung Injury; JE Repine, Principal Investigator.

Annual direct cost: \$1,049,022

Project 6: The Pathogenesis of ARDS - **Polly E. Parsons**, Principal Investigator;

Clinical Core - **Polly E. Parsons**, Principal Investigator.

NIH: NHLBI grant: NO1-HR46061; 9/94 - 9/01

Clinical Centers for a Clinical Network for ARDS.

Edward Abraham, Principle Investigator; **Polly E. Parsons** - Co-Principal Investigator.
Annual direct cost: \$107,542

NIH: NHLBI grant: HR-9421; 8/95 - 7/02

Clinical Network for Sarcoidosis

Lee S. Newman, Principal Investigator; **Polly E. Parsons** - Co-Investigator.

NIH:NHLBI: Special Request; 9/1999 - 9/2001

Biologic Markers in Clinical Lung Injury

Michael A. Matthay and **Polly E. Parsons**, Principal Investigators

Award: \$147,500

NIH:NHLBI – ARDSnet Clinical Trials

Subcontract for Prime Contract NO1-HR-46064

Polly E. Parsons, PI

7/01/00-5/06

HL076122 – C. Irvin (PI); **P. Parsons** (Co-PI)

NIH: NHLBI

Multidisciplinary Training in Lung Biology

4/1/2004-3/31/09

\$260,762

1 R13 HL103080-01

NIH: NHLBI

Multi-society Strategic Planning for Critical Care Research

Polly E. Parsons PI

3/1/2010

IU01HL102547 – M. Boeckh (PI)

NIH:NHLBI

A Randomized Phase II Trial of CMV Prevention in Acute Lung Injury

UVM Site PI: **P. Parsons**

6/1/10-5/31/13

1K23 HL105654- R. Stapleton (PI)

NIH :NHLBI

Pharmaconutrients as Therapies for Critical Illness : Zinc in Severe Sepsis

7/1/11-6/30/14

U01 HL108713-01- M. Matthay (PI)

NIH:NHLBI

"Allogeneic Human Mesenchymal Stem Cells for the Treatment of Acute Lung Injury".

UVM Site PI: **P. Parsons**

9/11-8/14

PROFESSIONAL SOCIETY MEMBERSHIPS

American Thoracic Society
Western Society of Clinical Medicine (elected)
Society of Critical Care Medicine
American College of Chest Physicians, Fellow
American College of Physicians, Fellow
Association of Professors of Medicine
Alliance for Academic Internal Medicine

REVIEWS AND REFEREE ACTIVITIES

Scientific Review:

American Lung Association, Research Grant Review Committee, 1991-1995

NIH: NHLBI: Clinical Trials Review Committee

Member, 1996 - 2000

Alternate Chairperson, 1999 – 2000

Ad hoc member: 2009

Special Emphasis Panel: member, 2005

Special Emphasis Panel SCCOR: Co-chair, 2006

Special Emphasis Panel: NIH Loan Repayment program: 2007 - 2011

Special Emphasis Panel: R-13 Conference Grants: 2007

AARA GO RC 2 application reviews: 2009

NHLBI Institutional Training (T32) Mechanism Review Group 2009-2010

NHLBI Scientific Advisory Council: member 2011-present

VA: Ad hoc reviewer, Department of Veterans Affairs Merit Review, 1996 -2000

UCHSC:UCB School of Engineering Grants: 1998

American Thoracic Society- Glaxo Fellowship Awards: 2007-2009

Scientific Council of the Francis Families Foundation: 2007-2011

Editorial Boards:

Women's Health in Primary Care 1998-2008

Up-to-Date: Editor-in-Chief, Critical Care Section 2004-present

American Journal of Respiratory and Critical Care Medicine 2005-present

CHEST 2005-present

Proceedings of the American Thoracic Society: 2006-2012

Journal Reviews:

American Review of Respiratory Disease

American Journal of Respiratory and Critical Care Medicine

Journal of Clinical Investigation

Journal of Laboratory and Clinical Investigation

Chest

Alcoholism: Clinical and Experimental Research

Critical Care Medicine

Journal of Applied Physiology

American Journal of Respiratory Cell and Molecular Biology
Journal of Infectious Disease
Journal of Respiratory Diseases
Journal of American Medical Association
AJP: Lung Cellular and Molecular Physiology

Other:

Ad Hoc Reviewer Scientific American Medicine, Respiratory Disease
External review panel: University of Washington Fellowship Training Program:
2007, 2012
AAIM external review SIU Department of Medicine, APM representative, 2012

HONORS AND AWARDS

America's Top Doctors: 2001, 2002, 2003, 2004, 2006, 2007, 2009, 2010, 2011
US News & World Report: Top 1% Pulmonary Physicians in the US 2012
American Thoracic Society Elizabeth A. Rich, MD Award Recipient: 2006
Selected as the Who's Who in the American Thoracic Society for October 2006.
American Thoracic Society Distinguished Achievement Award: May 2013

VISITING PROFESSORSHIPS

Northwestern University Medical School, May 1996
University of Michigan, December 1996
University of Vermont, December 1998
University of Calgary, Alberta Heritage Foundation for Medical Research (AHFMR) Visiting
Lecture Award, November 2003
University of Colorado, Thomas Neff Visiting Professor, January 2004
Mt Sinai School of Medicine, February 2008
Ohio State University, September 2008
University of Toronto, October 2012
University of Washington: John Butler Lecture Speaker November 2013

PROFESSIONAL SERVICE

National Organizations:

American Board of Internal Medicine:
Critical Care Medicine Test and Policy Committee, 1995 – 2001
General Internal Medicine Test and Policy Committee, 2001 – 2006
Recent Advances SEP Test-Writing Committee for Pulmonary Disease 2002-2005

American Thoracic Society:
Assembly on Critical Care:
Long Range Planning Committee 1993 – 1997

Nominating Committee 2000 – 2001
Planning Committee 2003 - 2004
American Journal of Respiratory and Critical Care Medicine Editor's Search
Committee, 1998
Membership Committee: 2002 – 2004
Training Committee: Member: 2004-2009
Chair: 2005-2008
Clinicians' Advisory Committee: 2005-2008
Minority Trainee Travel Award Review Committee: 2005-2008
Taskforce on Critical Care Medicine: 2005- 2006
Strategy Group: Workforce Development: member: 2005
ATS/GSK Development Awards committee: Co-chair 2007 – 2009
Program and Budget Committee: member 2007-2011
Members in Transition and Training Committee: member 2008-present
Publications Policy Committee: member 2011-2012
Finance Committee: member 2011- 2012
Nominating Committee: member 2013-2014

Review Panel, National Center for the State Courts, Research Division, 1995

Association of Pulmonary and Critical Care Medicine Program Directors:

Member: 2000-2010
Executive Committee, member: 2002-2010
Vice President: 2002- 2003
President-Elect: 2003-2004
President: 2004-2005

Association of Subspecialty Professors

Councilors: Member At-Large: 2003-2006
Professional Development Committee, member: 2004-2006

American College of Chest Physicians

Board of Regents: ex-officio member 2004- 2005
Government Relations Committee: liaison from APCCMPD 2004- 2005

Association of Professors of Medicine:

Education Committee: member: 2008-2011
Chair: 2010-2011
Board of Directors: 2010-2011
Nominating Committee: 2011- 2012
APM Council member: 2014-present
Robert H. Williams, MD, Distinguished Chair of Medicine Award selection committee 2015

American College of Physicians:

IM-ITE test writing committee: 2008-2011

Alliance for Academic Internal Medicine:

Fellowship Requirements Task Force: 2009-2010
Accreditation Committee: Chair 2011-2014
Board of Directors (ex-officio): 2011- 2014
ACGME Milestones project: 2013-2014
Governance Committee member: 2014-present
Education Committee member: 2014-present

Multi-society Task Force on Pulmonary Medicine and Critical Care Competencies:

Chair, 2006-2009

Multi-society National Task Force to Develop a Critical Care Research Agenda:

Chair: 2009 – 2013

National Institutes of Health:

NHLBI - Task Force on Research in Cardiopulmonary Dysfunction
Critical Care Medicine, 1993 – 1994

NHLBI - ARDS Clinical Trials Network I

Steering Committee, Member, 1995 - 2006
Pathogenesis Committee, Chair, 1997 - 2006
Natural History Committee, Member, 1997-2006
Institutional Review Committee
Member 1988 – 2006
Acting Chair 2000 – 2001

NHLBI - ARDS Clinical Trials Network II

Protocol Review Committee: member 2006 to present

NHLBI:FDA - Workshop on Pulmonary Artery Catheterization and Clinical Outcomes, Co-Chair Respiratory Diseases Group, 1997

NHLBI Working Group: Research Opportunities in the Clinical Epidemiology of Lung Injury and Critical Illness: 2000

NHLBI: Future Directions in Acute Lung Injury Workshop 2002

NHLBI Workshop on Adult Stem Cells, Lung Biology and Lung Diseases 2005

NIH US Critical Illness and Injury Trials Group:

Organizing Committee, member: 2007-2013

NIH Proteomics Programs: External Advisory Panel: 2007-2009

NHLBI Strategic SCCOR Planning Committee: 2009

NHLBI Next Generation Resuscitation Research Workshop 2013

NHLBI Cell Therapy Think Tank 2014

NHLBAC Asthma Expert Panel Working Group 2014

NHLBI Think Tank on Sickle Cell Disease 2014

Food and Drug Administration:

Pulmonary-Allergy Drugs Advisory Committee

Member: 2001-2004
Acting Chair: 2003-2004
Chair: 2004
Ad hoc member 2004-present

Center for Devices and Radiological Health Medical Devices Advisory Committee:
Anesthesiology and Respiratory Therapy Devices Panel: 2009

University of Colorado Health Sciences Center:

Pulmonary Division, Critical Care Committee, 1990 - 1994
Intern Selection Committee, Department of Medicine, 1995 - 2000
Pulmonary Division, Practice and Fellowship Committee, 1996 - 2000

Denver Health Medical Center:

Critical Care Committee, 1990 - 2000
Ethics Committee:
Member, 1993 - 2000
Vice Chair, 1996 - 1997
Chair, 1997 - 2000
Library Committee:
Member, 1995 - 2000
Chair, 1997 - 2000
Utilization Review Committee: 1991 - 1993
Department of Medicine Quality Assurance Committee, 1991 - 1993
Donor Task Force, 1994 - 2000
Search Committee, Chief of Gastroenterology,
Chair, 1997 - 1998

Fletcher Allen Health Care:

Critical Care Committee
Chair 2000 - 2009
Ethics Advisory Committee: 2001 - 2004
Internship Interview Committee: 2002-2005
ICU Initiatives Committee: member 2003-2009
Medical Staff: President -Elect: 2003- 2004
President: 2004-2005
Medical Executive Committee, member 2003-present
Chair 2004-2005
Mortality Review Committee, member 2004
Credentials Committee, member 2003 - 2006
By-laws Committee member 2003 -2006
Medical QA&I Committee: member 2004-2005
Board of Trustees: at large member 2004-2005
Board of Trustees: Quality Committee: member 2004-2005
Board of Trustees: Ethics Committee: member 2004-2005
Planning Steering Committee: member 2005
Strategic Management Committee: member 2005-present

Quality Council: member 2005-2006
UVMMG Board: member 2005-present
Vice Chair 2014-present
Faculty Practice Patient Care and Operations Committee: member 2005-2009
Faculty Practice Research and Education Committee: chair: 2010-2012
UVMMG Finance Committee: 2013-present
Network Development Advisory Committee: 2008-2010
UVMMG Practice Management Council: 2011-present
Academic Leadership Council 2013-present
Cancer Service Line Steering Committee: chair 2013-present
Cardiovascular Service Line Advisory Committee: 2014-present

University of Vermont:

Search Committee, Chair of Radiology, 2000 – 2002
College of Medicine Governance Task Force, Co-chair: 2004 – 2007
Vermont Cancer Center Advisory Board 2005-2010
Search Committee, Chief of Hematology-Oncology, Chair 2005-2009
Search Committee, Dean, College of Medicine: 2006-2007
Search Committee, Chief of Pulmonary and Critical Care Medicine, Chair 2006-2009
College of Medicine Dean's Advisory Council: 2005 – present
Search Committee, Vermont Cancer Center Director: 2007 –2009
Search Committee, Senior Associate Dean for Research: 2008-2009
UMEA Board member 2010-present
Faculty Panel, UVM President Search: 2011-2012
Strategic Values Financial Attractiveness Joint Committee, member 2012
Search Committee, Assistant Dean for Faculty, Chair 2012
LCME Task Force 2012-2013
COM LCME Accreditation Process, Subcommittee IV, Faculty, Chair 2012-2013
Search Committee, UVM Provost: 2013
UVM Incentive Based Budget:
Steering Committee member: 2013-present
Chair, Cost Pool Methodology Subcommittee
COM FTARS Review Committee, Chair: 2013-present

Other:

Biomedical Research Foundation:
Member, Board of Directors, 1995 - 2000
Vice President, Board of Directors, 1996 - 2000
Colorado Trudeau Society:
Secretary/Treasurer, 1996 - 1998
President-elect, 1998 – 2000
Aspen Lung Conference:
Co-Chair: Acute Lung Injury 1994

External Advisor: 2014-present
American Lung Association of Colorado:
Research Advisory Committee, 1998 - 2000
Acute Therapeutics, Inc:
Data Safety Monitoring Board: Phase 2/3 Trial of KL4-Surfactant
in ARDS, 2000
Discovery Labs, Inc:
Data Safety Monitoring Board 2001-2003

UHC Board of Trustees:
Member 2002-2008
President-elect 2005-2008
Member, Investment Advisory Committee: 2005-2008

MENTEES:

Marc Moss, M.D., 1992 - 1995; Professor, University of Colorado
Kevin Connelly, M.D. (with J.E. Repine, M.D.) 1994-1996; private practice
Sandra Lauriet, M.D. (with S.L. Linas, M.D.) 1996 – 1997; private practice
Robert Patterson, M.D. (with S.L. Linas, M.D.) 1997 – 1999; private practice
Gilman Allen, M.D. (with Jason Bates, PhD) 2001-2003: Associate Professor, UVM
Renee Stapleton MD, PhD 2007-present: Associate Professor, UVM

PUBLICATIONS

1. Parsons PE and Taylor CR. Energetics of brachiation versus walking. *Physiol Zool* 50:182-189, 1977.
2. Parsons PE, Fowler AA, Hyers TM, Henson PM. Chemotactic activity in bronchoalveolar lavage fluid from patients with ARDS. *Am Rev Respir Dis* 132:490-493, 1985.
3. Sugahara K, Cott GR, Parsons PE, Mason RJ, Sandhaus RA, Henson PM. Epithelial permeability produced by activated neutrophils in vitro: inhibition by alpha₁- protease inhibitors and catalase. *Am Rev Respir Dis* 133:875-881, 1986.
4. Rodman DM, Hanley ME, Parsons PE. Aminoglutathione, alveolar damage and hemorrhage. *Ann Intern Med* 105(4):633, 1986.
5. Parsons PE, Sugahara K, Cott GR, Mason RJ, Henson PM. The effect of neutrophil migration and prolonged neutrophil contact on epithelial permeability. *Am J Pathol* 129:302-312, 1987.
6. Peterson VM, Moore EE, Jones TN, Rundus C, Moore FA, McCroskey BL, Haddix T, Emmett M, Parsons PE. Total enteral nutrition versus total parenteral nutrition following major torso injury: Attenuation of hepatic reprioritization. *Surgery* 104(2):199-207, 1988.
7. Parsons PE, Worthen, GS, Moore EE, Tate RM, Henson PM. The association of circulating endotoxin with the development of the adult respiratory distress syndrome. *Am Rev Respir Dis* 140:294-301, 1989.
8. Parsons PE, Grunstein MM, Fernandez E. The effects of acute hypoxia and hypercapnia on pulmonary mechanics. *Chest* 96:96-101, 1989.

9. Moore FA, Moore EE, Haenel JB, Waring BJ, Parsons PE. Post-traumatic pulmonary pseudocyst in the adult: Pathophysiology, recognition and selective management. *J Trauma* 29(10):1380-1385, 1989.
10. Parsons PE and Giclas PC. The terminal complex of complement (sC5b-9) is not associated with the development of ARDS. *Am Rev Respir Dis* 141(1):98-103, 1990. (Note: This article was selected by the editor of *Respiratory Diseases Digest* as being outstanding in its field and an abstract of its contents was requested by that journal for publication - reference #11).
11. Parsons PE and Giclas PC. The terminal complement complex (sC5b-9) is not specifically associated with the development of the Adult Respiratory Distress Syndrome. *Respiratory Diseases Digest* 6:6-7, 1990.
12. Forrester JM, Steele AW, Waldren JA, Parsons PE. Crack Lung: A heterogeneous disorder with a potential role for systemic corticosteroids in selected cases. *Am Rev Respir Dis* 146(2):462-467, 1990.
13. Brown MA, McIntosh JC, Pfeffer K, Parsons PE. Relation between tumor necrosis factor- α and granulocyte elastase α -1 proteinase inhibitor complexes in the plasma of patients with cystic fibrosis (letter to the editor). *Am Rev Respir Dis*. 142(4):984-985, 1990.
14. McAnena O, Moore FA, Moore EE, Jones TN, Parsons PE. Selective uptake of glutamine in the gastrointestinal tract - confirmation in a human study. *British J Surg*. 78:408-482, 1991.
15. Moore FA, Moore EE, Pogetti R, McAnena OJ, Abernathy CM, Peterson VM, Parsons PE. Gut bacterial translocation via the portal vein: A clinical perspective in patients with major torso trauma. *J Trauma* 31:629-36, 1991.
16. McClellan MD, Miller S, Parsons PE, Cohn DL. Incidence and clinical characteristics of pneumothorax with pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. *Chest* 100:1224-1228, 1991.
17. Poggetti RS, Moore EE, Moore FA, Bensard DD, Parsons PE, Anderson BO, Banerjee N. Gut and liver coordinated metabolic response following major torso injury, *J Surgical Research*. 52:27-33, 1992.
18. Parsons PE, Moore FA, Moore EE, Ikle D, Henson PM, Worthen GS. Studies on the role of tumor necrosis factor in ARDS: The lack of an independent standard, *Am Rev Resp Dis* 146: 694-700, 1992.
19. Linas SL, Whittenburg D, Parsons PE, Repine SE. Mild renal ischemic activates primed neutrophils to cause acute renal failure. *Kidney International* 42:610-616, 1992.
20. Leff JA, Parsons PE, Day CE, Oppegard MA, Moore EE, Moore FA, Repine JA. Increased hydrogen peroxide scavenging and catalase activity in serum from septic patients who subsequently develop ARDS. *Am Rev Resp Dis* 146:985-989, 1992.
21. Leff JA, Parsons PE, Day CE, Taniguchi N, Jochum M, Fritz H, Moore FA, Moore EE, McCord JM, Repine JE. Serum antioxidants as predictors of adult respiratory distress syndrome. *Lancet* 341:777-780, 1993.
22. Dauber IM, Parsons PE, Welsh CH, Giclas PC, Glen JR, Whitman GJ, Wheeler GS, Horowitz LD, Weil JV. Peripheral bypass-induced pulmonary and coronary vascular injury: Association with increased levels of tumor necrosis factor. *Circulation* 88:726-735, 1993.
23. Parsons PE, Kobayashi J, Gabow P. Futile care: Prevention and Process. *J. Critical Illness*. 9:856-69, 1994.

24. Moss M, Ackerson L, Gillespie MK, Moore FA, Moore EE, **Parsons PE**. Von Willebrand factor antigen levels do not predict the development of the Adult Respiratory Distress Syndrome. *Amer J. Resp. and Crit Care Med.* 151:15-20, 1995.
25. **Parsons PE**, Gillespie MK, Moore EE, Moore FA, Worthen GS. Neutrophil response to endotoxin in the adult respiratory distress syndrome: Role of CD14. *Amer. J. Resp. Cell and Mol. Biol.* 13:152-60, 1995.
26. Moss M, Goodman PL, Heinig M, Barkin S, Ackerson L, **Parsons PE**. Establishing the accuracy of two new definitions of the Adult Respiratory Distress Syndrome. *Critical Care Medicine* 23:1629-37, 1995.
27. Linas SL, Whittenburg D, **Parsons PE**, Repine JE. Ischemia increases neutrophil retention and worsens acute renal failure. *Kidney International* 48:1584-91, 1995.
28. Moss M, Bucher B, Moore FA, Moore EE, **Parsons PE**. Predicting the development of the Adult Respiratory Distress Syndrome: The role of chronic alcohol abuse. *JAMA.* 275:50-54, 1996.
29. Apolone G, Blanch JY, Fagon JY, Foex P, Hedenstierna G, Lemaire F, Morel D, **Parsons PE**, Pesenti A, Ramsey G, Simbruner G, Slutsky A. Tissue hypoxia: how to detect, how to correct, how to prevent? *Reanimation Urgences.* 5:163-173, 1996.
30. Moss M, Gillespie MK, Ackerson L, Moore FA, Moore EE, **Parsons PE**. Endothelial cell activity varies in patient at risk for the Adult Respiratory Distress Syndrome. *Critical Care Med.* 24:1782-1786, 1996.
31. Bursten SL, Federighi DA, **Parsons PE**, Harris WE, Abraham E, Moore EE, Moore FA, Bianco JA, Singer JW, Repine JE. An increase in serum C18 unsaturated free fatty acids as a predictor of the development of acute respiratory distress syndrome. *Crit Care Med.* 24:1129-36, 1996.
32. Connelly KG, Moss M, **Parsons PE**, Moore EE, Moore FA, Giclas PC, Seligman PA, Repine JE. Serum ferritin as a predictor of the acute respiratory distress syndrome. *Am J Resp and Crit Care Med.* 155:21-25, 1996.
33. **Parsons PE**, Moss M, Vannice J, Moore EE, Moore FA, Repine JE. Circulating IL-1ra and IL-10 levels are increased but do not predict the development of ARDS in at risk patients. *Am J. Resp and Crit Care Med,* 155:1469-73, 1997.
34. Chan ED, Hodges TN, **Parsons PE**. Sudden respiratory insufficiency in a previously healthy 47 year old man. *Chest.* 155:1469-73, 1997.
35. Moss M, **Parsons PE**. What is the acute respiratory distress syndrome? *J. Intensive Care Medicine.* 13:59-67, 1998.
36. **Parsons, PE** and Matthay, MA. Protective ventilation for the acute respiratory distress syndrome. *NEJM* 339:197, 1998.
37. Greene KE, Ye S, Mason RJ, **Parsons PE**. Serum SP-A levels predict development of ARDS in at-risk patients. *Chest* 116:90 S, 1999.
38. Moss M, Steinberg KP, Guidot DM, Duhon GF, Treece P, Wolken R, Hudson LD, **Parsons PE**. The effect of chronic alcohol abuse on the incidence of ARDS and the severity of multiple organ dysfunction syndrome in adults with septic shock; An interim and multivariant analysis. *Chest* 116:97 S, 1999.
39. Abraham E, Dinarello CA, Matthay MA, Vincent JL, Cohen J, Opal SM, Glauser M, **Parsons PE**, Fisher CJ, Repine JE. Consensus conference definitions for sepsis, septic shock, acute lung injury and ARDS-Time for re-evaluation. *Critical Care Medicine,* 28:232-235, 2000
40. Moss M, Steinberg KP, Guidot DM, Duhon GF, Treece P, Wolken R, Hudson LD,

- Parsons PE**. Diabetic patients with septic shock have a decreased incidence of the acute respiratory distress syndrome. *Critical Care Medicine*, 28:2187-2192,2000
41. Bernard GR, Sopko G, Cerru F, Demling R., Edmunds H, Kaplan S, Kessler L, Mosur H, **Parsons PE**, Shure D, Webb C, Weidemann H, Weinman G, Williams D. National Heart, Lung and Blood Institute and Food and Drug Administration Workshop Report: Pulmonary Artery Catheterization and Clinical Outcomes (PACCO) *JAMA* 283:2568-72, 2000.
 42. Thompson BT, Hayden D, Matthay MA, Brower R, **Parsons PE**, Clinicians' approaches to mechanical ventilation in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) *CHEST* 2001; 120:1622-1627.
 43. Allen G, **Parsons PE**, Bates J. The transient mechanical benefits of a deep inflation in the injured mouse lung. *JAP* 2002;93:1709-1715
 44. Moss M, **Parsons PE**, Steinberg KP, Hudson LD, Guidot DM, Burnham EL, Eaton S, Cotsonis GA. Chronic alcohol abuse is associated with an increased incidence of ARDS and severity of multiple organ dysfunction in patients with septic shock. *Critical Care Medicine* 2003; 31:869-877
 45. Matthay MA, Zimmerman GA², Esmon C, Bhattacharya J, Coller B, Doerschuk CM, Floros J, Gimbrone MA, Jr., Eric Hoffman, Rolf D. Hubmayr¹, Mark Leppert, Sadis Matalon, Robert Munford, **Parsons P**, Arthur Slutsky, Kevin J. Tracey, Peter Ward, Dorothy B. Gail, Andrea L. Harabin. Future research directions in acute lung injury: Summary of a National Heart, Lung and Blood Institute Working Group. *AJRCCM* 2003; 167:1027-1035.
 46. Eisner MD, **Parsons P**, Matthay MA, Ware L, Greene K. Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. *Thorax* 2003; 58:983-988.
 47. **Parsons PE**. Commentary: Bridging the Chasm Between Bench and Bedside: Translational Research in Acute Lung Injury. *Am J Physiol Lung Cell Mol* 2004; 286:L1086-L1087
 48. Young MP, Manning HL, Wilson DL, Mette SA, Riker RR, Leiter JC, Liu SK, Bates JT, **Parsons PE**. Ventilation of patients with acute lung injury and ARDS: Has science changed clinical practice? *Critical Care Medicine* 2004; 32:1260-1265.
 49. Ware LB, Eisner MK, Thompson T, **Parsons PE**, Matthay MA. Evidence for endothelial injury in both septic and non-septic patients with acute lung injury *AJRCCM* 170:766-772, 2004
 50. **Parsons PE**, Eisner MD, Thompson BT, Matthay MA, Ancukiewicz M, Bernard GR, Wheeler AP. Lower tidal volume ventilation strategy and plasma cytokine markers of inflammation in patients with acute lung injury. *Critical Care Medicine* 33: 1-6, 2005
 51. **Parsons PE**, Matthay MA, Ware LB, Eisner MD and the Acute Respiratory Distress Syndrome Network. Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury (*Am J Physiol Lung Cell Mol* : 288:L426-L431, 2005 (e pub Oct 29, 2004)
 52. Frank JA, **Parsons PE**, Matthay MA. Pathogenetic significance of biologic markers of ventilator associated lung injury in experimental and clinical studies. *Chest* 130:1906-1914, 2006
 53. Ware LB, Matthay MA, **Parsons PE**, Thompson BT, Eisner MD and the NHLBI Acute Respiratory Distress Syndrome Clinical Trials Network. Pathogenic and prognostic significance of altered coagulation and fibrinolysis in patients with acute lung injury. *Critical Care Medicine* 35:1821-1828, 2007 (e pub June 19, 2007)
 54. Liu KD, Glidden DV, Eisner MD, **Parsons PE**, Ware LB, Wheeler A, Korpak A, Thompson BT, Chertow GM, Matthay MA and the NHLBI ARDS Network Clinical Trials Group. Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury. *Critical Care Medicine* 35:2755-2761, 2007 (e pub October 23, 2007)

55. Calfee CS, Eisner MD, Ware LB, Thompson BT, **Parsons PE**, Wheeler AP, Korpak A, Matthay MA. Trauma associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders. *Critical Care Medicine* 35: 2243-2250, 2007 (e pub July 17, 2007)
56. Calfee CS, Ware LB, Eisner MD, **Parsons PE**, Thompson BT, Wickersham N, Matthay MA. And the NHLBI ARDS network. Plasma receptors for advanced glycation end-products and clinical outcomes in acute lung injury *Thorax*, 63:1083-1089, 2008 (e pub June 19, 2008)
57. Calfee CS, Eisner MD, **Parsons PE**, Thompson BT, Conner ER, Matthay MA and the NHLBI Acute Respiratory Distress Syndrome Clinical Trials Network. Soluble intercellular adhesion molecule-1 and clinical outcomes in patients with acute lung injury. *Intensive Care Medicine* 35:248-257, 2009 (e pub August 1, 2008)
58. Suratt BT, Eisner MD, Calfee CS, Allard JB, Whittaker LA, Engelken DT, Petty JM, Trimarchi T, Gauthier L, **Parsons PE**; NHLBI Acute Respiratory Distress Syndrome Network. Plasma granulocyte colony-stimulating factor levels correlate with clinical outcomes in patients with acute lung injury. *Critical Care Medicine* Feb 24, 2009 (epub ahead of print)
59. Buckley JD, Addrizzo-Harris DJ, Clay AS, Curtis JR, Kotloff RM, Lorin SM, Murin S, Sessler CN, Rogers PL, Rosen MJ, Spevetz A, King TE Jr, Malhotra A, **Parsons PE**. Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine. *Am J Respir Crit Care Med*. 2009 August 15; 180(4): 290-295
60. Cobb JP, Cairns CB, Bulger E, Wong HR, **Parsons PE**, Angus DC, Gentile NT, Hoyt DB, Schwinn DA, Wiener-Kronish JP, Upperman JS. The United States critical illness and injury trials group: an introduction. *J. Trauma* S 159060, 2009.
61. Stapleton RD, Dixon AE, **Parsons PE**, Ware LB, Suratt BT. The Association between Body Mass Index and Plasma Cytokine Levels in Patients with Acute Lung Injury. *Chest* 138:568-577 2010; (epub April, 2010). PMID: 20435651
62. Calfee CS, Thompson BT, **Parsons PE**, Ware LB, Matthay MA, Wong HR. Plasma interleukin-8 is not an effective risk stratification tool for adults with vasopressor-dependent septic shock. *Crit Care Med*. 2010 Jun;38(6):1436-41. PMID: 20386309
63. Calfee CS, Ware LB, Glidden DV, Eisner MD, **Parsons PE**, Thompson BT, Matthay; National Heart, Blood, and Lung Institute Acute Respiratory Distress Syndrome Network. Use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injury. *Crit Care Med* 39:711-717 2011 (epub ahead of print 1-28-2011). PMID:21283009
64. Stapleton RD, Martin TR, Weiss NS, Crowley JJ, Gundel SJ, Nathens AB, Akhtar SS, Ruzinski JT, Caldwell E, Curtis JR, Heyland DK, Watkins TR, Martin JM, **Parsons PE**, Wurfel MM, Hallstrand TS, Sims KA, Neff MJ. A Phase II Randomized Placebo-Controlled Trial of Omega-3 Fatty Acids for the Treatment of Acute Lung Injury. *Crit Care Med* 39:1655-1662 2011 (epub ahead of print 3-17-2011). PMID:21423000
65. Deutschman C D, Ahrens T, Cairns CB, Sessler CN, **Parsons PE** for the Critical Care Societies Collaborative/USCIITG Task Force on Critical Care Research. Multi-Society Task Force for Critical Care Research: Key issues and Recommendations. *Chest* 2012;141:198-200,201-209 PMID:22215828
66. Deutschman C D, Ahrens T, Cairns CB, Sessler CN, **Parsons PE** for the Critical Care Societies Collaborative/USCIITG Task Force on Critical Care Research. Multi-Society Task Force for

- Critical Care Research: Key issues and Recommendations: Executive summary. Chest 141:198-200, 2012. PMID: 22215827
67. Deutschman C D, Ahrens T, Cairns CB, Sessler CN, **Parsons PE** for the Critical Care Societies Collaborative/USCIITG Task Force on Critical Care Research. Multi-Society Task Force for Critical Care Research: Key issues and Recommendations. Am J Respir Crit Care Med 2012; 185: 96-102. PMID:22210788
 68. Deutschman C D, Ahrens T, Cairns CB, Sessler CN, **Parsons PE** for the Critical Care Societies Collaborative/USCIITG Task Force on Critical Care Research. Multi-Society Task Force for Critical Care Research: Key issues and Recommendations. Am J Crit Care 2012; 21:12-14. PMID:22298714
 69. Deutschman C D, Ahrens T, Cairns CB, Sessler CN, **Parsons PE** for the Critical Care Societies Collaborative/USCIITG Task Force on Critical Care Research. Multi-Society Task Force for Critical Care Research: Key issues and Recommendations. Crit Care Med 2012; 40:254-260.
 70. Deutschman C D, Ahrens T, Cairns CB, Sessler CN, **Parsons PE** for the Critical Care Societies Collaborative/USCIITG Task Force on Critical Care Research. Multi-Society Task Force for Critical Care Research: Key issues and Recommendations. Crit Care Nurse 32:16-18, 2012. PMID: 22298714
 71. Elliott CG and **Parsons PE**. Update in Pulmonary and Critical Care Medicine: Evidence Published in 2011. Annals of Internal Medicine 156:736-742, 2012
 72. Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA and the NHLBI ARDS Network. Latent class analysis of ARDS subphenotypes: Analysis of data from two randomized controlled trials. Lancet Respiratory Medicine 2:611-20, 2014 (Epub 2014 May 19). PMID:24853585
 73. Ben-Ari R, Robbins RJ, Pindprolu S, Goldman A, **Parsons PE**. The Costs of Training Internal Medicine Residents in the U.S. American Journal of Medicine 127:1017-1023, 2014. PMID:25063649

CHAPTERS, REVIEWS AND EDITORIALS

1. **Parsons PE**. New pathogens in the ICU. Pulmonary Crit Care Rev 2:1-8, 1986.
2. Henson PM, Tonneson MG, Worthen GS, **Parsons PE**. Mechanisms and effects of accumulation of inflammatory cells. In: Proceedings of the First Capri Conference on Clinical Immunology, G Maronne (editor), BC Decker, Toronto, Canada, 1987.
3. **Parsons PE**. Pulmonary manifestations of the acquired immunodeficiency syndrome. In: Synopsis in Pulmonary Medicine, RS Mitchell, TL Petty and MI Schwarz (eds), St. Louis, Missouri, 1988. C.V. Mosby Company.
4. **Parsons PE**. Pulmonary infections in the immunocompromised host. In: Synopsis in Pulmonary Medicine, RS Mitchell, TL Petty and MI Schwarz (eds), St. Louis, Missouri, 1988. CV Mosby Company.
5. **Parsons PE**, Worthen GS, Henson PM. Injury from inflammatory cells. In: The Lung: Scientific Foundations, RG Crystal and JB West (eds), New York, New York, Raven

- Press 1991.
6. **Parsons PE**. The solitary pulmonary nodule. In: Surgical Secrets, C Abernathy (editor), Hanley & Belfus, Inc., Philadelphia, PA 1991.
 7. **Parsons PE**. Pulmonary disease during pregnancy. In: Obstetrical Secrets, L Wilkins and H Fredrickson (eds). Hanley & Belfus Inc, Philadelphia, PA 1991.
 8. **Parsons PE**, Worthen GS, Henson PM. Injury from inflammatory cells. In: Lung Injury, RG Crystal and JB West (eds), New York, New York, Raven Press 1991.
 9. **Parsons PE**. Adult Respiratory Distress Syndrome. In: Critical Care Secrets, PE Parsons and J Weiner-Kronish, (eds). Hanley & Belfus, Inc., Philadelphia, PA 1992.
 10. **Parsons PE** and Murahata SA. Acute obstetrical problems in the ICU. In: Critical Care Secrets, PE Parsons and J Weiner-Kronish, (eds) Hanley & Belfus Inc., Philadelphia, PA 1992.
 11. **Parsons PE** and Neff TA. Pulmonary embolism. In: Critical Care Secrets, PE Parsons and J Weiner-Kronish, (eds). Hanley & Belfus, Inc. Philadelphia PA 1992.
 12. **Parsons PE**. DVT/Pulmonary Embolism. In: Emergency Medicine Secrets, P Pons and V Markovchick, (eds). Hanley & Belfus, Inc., Philadelphia, PA 1993.
 13. **Parsons PE**. Acute respiratory failure due to drugs, overdoses and poisonings. In: Clinics in Chest Medicine, 15:93-102, 1994.
 14. Henson PM, Doherty DE, Riches DWH, **Parsons PE**, Worthen GS. LPS and cytokines in lung injury. In: Endotoxin and the Lungs, KL Brigham (editor). Marcel Decker, Inc. New York, New York, 1994.
 15. Aronsen EL and **Parsons PE**. Evaluation of a Lung Mass. In: Hematology/Oncology Secrets, ME Wood and PA Bunn (eds). Hanley and Belfus, Inc. Philadelphia, PA 1994.
 16. Moss M and **Parsons PE**. Mechanical Ventilation and the Adult Respiratory Distress Syndrome. In: Seminars in Respiratory Medicine, 15:289-99, 1994.
 17. Repine JE and **Parsons PE**. Oxidant-Antioxidant Balance in Endotoxin Induced Oxidative Injury. In: Endotoxin and the Lungs, KL Brigham (editor), Marcel Decker, Inc. New York, New York, 1994
 18. **Parsons PE**. Complement, Endotoxin and ARDS. In: The Adult Respiratory Distress Syndrome, C Haslett and T Evans, (eds) Chapman & Hall. 1996
 19. **Parsons PE** and Moss M. Early detection and markers of sepsis. In: Clinics in Chest Medicine. 17:199-212, 1996.
 20. Aronsen EL and **Parsons PE**. Pulmonary Disease in Pregnancy. In: Obstetrical Secrets, 2nd Edition, L Wilkins-Haug, (ed), Hanley & Belfus, Philadelphia, PA. p199-200, 1996.
 21. **Parsons PE**, Worthen GS, Henson PM. Injury from Inflammatory Cells. In: The Lung Scientific Foundation, 2nd edition, RG Crystal and JB West (eds), Raven Press, New York, New York. p 2439-2450, 1996.
 22. **Parsons PE**. Disorders of the Mediastinum. In: Pulmonary and Respiratory Pulmonary Therapy Secrets. PE Parsons and JE Heffner, (eds), Hanley & Belfus, Philadelphia, PA. p 418-420, 1996.
 23. **Parsons PE** and Heffner JE. Chest wall disorders. In: Pulmonary and Respiratory Therapy Secrets. PE Parsons and JE Heffner, (eds), Hanley & Belfus, Philadelphia, PA. p 420-422, 1996.
 24. **Parsons PE** and Tu YP. Thoracentesis and Percutaneous Pleural Biopsy. In: Pulmonary and Respiratory Therapy Secrets. PE Parsons and JE Heffner, (eds). Hanley & Belfus, Philadelphia, PA. p 59-62, 1996.

25. **Parsons PE** and Moss M. Circulating markers of sepsis and acute lung injury. In: Sepsis and Multiorgan Failure: Mechanisms for treatment strategies. AM Fein et al (eds). Williams & Wilkins, Media PA. p 277-285, 1998.
26. **Parsons PE**. Contribution to: Critical Care Pearls, 2nd edition, SA Sahn and JE Heffner, (eds), Hanley & Belfus, 1998.
27. Greene KE and **Parsons PE**. Complement and Endotoxin in Acute Lung Injury. In: Update in Intensive Care and Emergency Medicine, J.L. Vincent, editor. Springer-Verlag, Berlin. p 54-69, 1998.
28. **Parsons PE**. Acute Respiratory Distress Syndrome. In: Critical Care Secrets, 2nd edition, PE Parsons and J Weiner-Kronish (eds), Hanley & Belfus, Inc. Philadelphia, PA. p 121-124, 1998.
29. **Parsons PE**. IL-10 The Ambiguity in Sepsis Continues. Critical Care Medicine. 26:818-819, 1998.
30. **Parsons PE**. Deep Venous Thrombosis and Pulmonary Embolism. In: Emergency Medicine Secrets, 2nd edition, P. Parsons and V. Markovchick (eds), Hanley & Belfus, Inc. Philadelphia, PA, 1999.
31. Aronsen EL and **Parsons PE**. Evaluation of a Lung Mass. In: Hematology/Oncology Secrets, 2nd edition, Marie Wood (ed), Hanley & Belfus, Inc. Philadelphia, PA, 1999.
32. **Parsons PE**. Mediators and Mechanisms of Lung Injury. Clinics in Chest Medicine 21:467-476, 2000.
33. **Parsons PE**. Disorders of the Mediastinum in Pulmonary and Respiratory Therapy Secrets. 2nd edition. PE Parsons and JE Heffner (eds), Hanley & Belfus, Philadelphia, PA 2001.
34. **Parsons PE** and Heffner JE, Chest Wall Disorders in Pulmonary and Respiratory Therapy Secrets, 2nd edition. PE Parsons and JE Heffner (eds) Hanley & Belfus, Philadelphia, PA 2001.
35. Tu YP and **Parsons PE** Thoracentesis and Percutaneous Pleural Biopsy in Pulmonary/Respiratory Therapy Secrets, 2nd edition. PE Parsons and JE Heffner (eds) Hanley & Belfus, Philadelphia, PA 2001
36. Turki, M and **Parsons PE**. Acute Respiratory Distress Syndrome. In: Critical Care Secrets, 3rd edition, PE Parsons and J Weiner-Kronish (eds), Hanley & Belfus, Inc. Philadelphia, PA 2002
37. Bakes K and Parsons PE. Deep Venous Thrombosis and Pulmonary Embolism. In: Emergency Medicine Secrets. Markovchick VJ and Pons PT (eds). Hanley & Belfus, Inc. Philadelphia, PA 2002
38. **Parsons PE**. Progress in research on pulmonary-artery catheters. NEJM; 66-68, 2003.
39. Philips GK and **Parsons PE**. Evaluation of a Lung Mass. In: In: Hematology/Oncology Secrets, 3rd edition, Marie Wood and George K. Philips (ed), Hanley & Belfus, Inc. Philadelphia, PA, 2003.
40. **Parsons PE**. Acute Respiratory Distress Syndrome. In: Current Diagnosis and Treatment in Pulmonary Disease. M. Hanley and C. Welsh (eds). McGraw-Hill, NYC, NY. 2004.
41. Allen GB and **Parsons PE**. Acute Lung Injury: Significance, treatment and outcomes. Curr Opin Anaesthesiol. 2005 Apr;18(2):209-15.
42. Tu YP and **Parsons PE** Thoracentesis and Percutaneous Pleural Biopsy in Pulmonary/Respiratory Therapy Secrets, 3rd edition. PE Parsons and JE Heffner (eds) Hanley & Belfus, Philadelphia, PA 2006

43. **Parsons PE**, Eisner MD, Matthay MA, Thompson BT, Ancukiewicz M, Vernard GR, Wheeler AP. Is interleukin-6 clinically relevant? *Critical Care Medicine* 33: 1893, 2005.
44. Patel, K and **Parsons PE**. Acute Respiratory Distress Syndrome. In : *Critical Care Secrets*, 4th edition, PE Parsons and J Weiner-Kronish, (eds), Elsevier, Philadelphia, PA 2007
45. Allen GB and **Parsons PE**. Acute respiratory failure due to Acute Respiratory Distress Syndrome and Pulmonary Edema in: *Intensive Care Medicine*, Irwin and Rippe, 6th Edition, 2008
46. Suratt BT and **Parsons PE**. Mechanisms of acute lung injury. In: *Clinics in Chest Medicine* 27:579-589, 2006
47. **Parsons PE**. Evolution, In: Career Talk: <http://www.thoracic.org/sections/career-development/career-talk/articles/academia/November-2006.html>
48. **Parsons, PE**. Respiration in: *Body: The Complete Human*, National Geographic Society, Washington, DC
49. **Parsons PE**. Genetics, Iron and ALI: An intriguing relationship. *Chest* 133: 1295-1296, 2008
50. Allen GB and **Parsons PE**. Acute respiratory failure due to Acute Respiratory Distress Syndrome and Pulmonary Edema in: *Intensive Care Medicine*, Irwin and Rippe, 7th Edition, (2012)
51. **Parsons PE**, Acute Lung Injury in: *The Netter Collection of Medical Illustrations*, volume 3: Respiratory System, DA Kaminsky, editor, Elsevier, Philadelphia PA, 2011

BOOKS

1. *Critical Care Secrets*. **Polly E. Parsons** and Jeanine Weiner-Kronish, editors, Hanley & Belfus, Philadelphia, PA 1992.
2. *Pulmonary and Respiratory Therapy Secrets*. **Polly E. Parsons** and John E. Heffner, editors, Hanley & Belfus, Philadelphia, PA 1996.
3. *Bedside Critical Care Manual*. E.D. Chan, B.W. Wilson, L.S. Terada, **P.E. Parsons**. Hanley & Belfus, Philadelphia, PA 1997.
4. *Critical Care Secrets, Second Edition*, **Polly E. Parsons** and Jeanine Weiner-Kronish, editors, Hanley & Belfus, Philadelphia, PA 1998.
5. *Pulmonary / Respiratory Therapy Secrets, Second Edition*, **Polly E. Parsons** and John E. Heffner, editors, Hanley & Belfus, Philadelphia, PA 2002
6. *Critical Care Secrets, Third Edition*, **Polly E. Parsons** and Jeanine Weiner-Kronish, editors, Hanley & Belfus, Philadelphia, PA 2003
7. *Pulmonary/Respiratory Therapy Secrets, Third Edition*, **Polly E. Parsons** and John Heffner, editors, Elsevier, Philadelphia, PA 2006
8. *Critical Care Secrets, Fourth Edition*, **Polly E. Parsons** and Jeanine Weiner-Kronish, editors, Elsevier, Philadelphia, PA 2007
9. *Critical Care Secrets, Fifth Edition*, **Polly E. Parsons** and Jeanine Weiner-Kronish, editors, Elsevier/Mosby St. Louis, MO. 2012

GUEST EDITOR CONTRIBUTIONS

1. The Adult Respiratory Distress Syndrome. *Seminars in Respiratory Medicine*. **Polly E. Parsons**, editor. Volume 15, 1994.

2. Acute Lung Injury. Chest. G. Scott Worthen and Polly E. Parsons, editors Volume 105, 1994.

PUBLISHED COMMITTEE/CONSENSUS REPORTS/COLLABORATIVE TRIALS

1. National Heart, Lung, and Blood Institute Report of the Task Force on Research in Cardiopulmonary Dysfunction in Critical Care Medicine, U.S. Department of Health and Human Services, 1994.
2. Tissue Hypoxia: How to detect how to correct, how to prevent. Am J Respir Crit Care Med 154:1573-1578, 1996.
3. Round Table Conference: Acute Lung Injury. Am J Respir Crit Care 158:675-679, 1998.
4. A trial of traditional versus a lower total volume strategy in acute lung injury and the acute respiratory distress syndrome. The ARDS Network. NEJM 342:1301-1308, 2000.
5. A randomized placebo controlled trial of ketoconazole for early treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome. The ARDS Network NIH:NHLBI, JAMA 283:1995, 2000.
6. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. The ARDS Network NIH:NHLBI, Critical Care Medicine 30:1-6, 2002
7. Effects of recruitment maneuvers in patients with acute lung injury and acute respiratory distress syndrome ventilated with high positive end-expiratory pressure, ARDS Clinical Trials Network, NHLBI, NIH, Critical Care Medicine 31:2592-2597, 2003
8. Higher versus lower positive end expiratory pressure in patients with acute respiratory distress syndrome. NIH:NHLBI ARDS Clinical Trials Network. NEJM 351:327-336, 2004
9. Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, Thompson, Ancukiewicz M; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. NEJM 354:1671-1684, 2006
10. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network; Wheeler AP, Bernard GR, Thompson BT, Schoenfeld D, Wiedemann HP, deBoisblanc B, Connors AF Jr, Hite RD, Harabin AL. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. NEJM 2006 May 25;354(21):2213-24. Epub 2006 May 21.
11. The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of Two Fluid-Management Strategies in Acute Lung Injury NEJM 354:2564-2575, 2006
12. McClintock DE, Starcher B, Eisner MD, Thompson BT, Hayden DL, Church GD, Matthay MA and the National Heart, Lung, Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Higher urine desmosine levels are associated with mortality in patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol. 291: L566-L571, 2006
13. McClintock DE, Ware LB, Eisner MD, Wickersham N, Thompson BT, Matthay MA and the National Heart, Lung, and Blood Institute ARDS Network. Higher urine nitric oxide is associated with improved outcomes in patients with acute lung injury. Am J Respir Crit Care Med 175:256-262, 2007
14. Glassberg AE, Luce JM, Matthay MA; National Heart, Lung, and Blood Institute Clinical Trials Network. Reasons for non-enrollment in a trial of acute lung injury. Chest. 134(4):719-23. (Epub

- 2008 Aug 8.), 2008
15. Ware LB, Koyama T, Billheimer DD, Wu W, Bernard GR, Thompson BT, Brower RG, Standiford TJ, Martin TR, Matthay MA; NHLBI ARDS Clinical Trials Network.; Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. *Chest*. 2010 Feb;137(2):288-96. (Epub 2009 Oct 26)
 16. Liu KD, Thompson BT, Ancukiewicz M, Steingrub JS, Douglas IS, Matthay MA, Wright P, Peterson MW, Rock P, Hyzy RC, Anzueto A, Truwit JD; National Institutes of Health National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network. Acute kidney injury in patients with acute lung injury: impact of fluid accumulation on classification of acute kidney injury and associated outcomes. *Crit Care Med*. 2011 Dec;39(12):2665-71.
 17. Rice TW, Wheeler AP, Thompson BT, deBoisblanc BP, Steingrub J, Rock P; NIH NHLBI Acute Respiratory Distress Syndrome Network of Investigators. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. *JAMA*. 2011 Oct 12;306(14):1574-81. Epub 2011 Oct 5.
 18. Initial trophic vs full enteral feeding in patients with acute lung injury: the EDEN randomized trial. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Rice TW, Wheeler AP, Thompson BT, Steingrub J, Hite RD, Moss M, Morris A, Dong N, Rock P, *JAMA*. 2012 Feb 22;307(8):795-803. Epub 2012 Feb 5
 19. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Matthay MA, Brower RG, Carson S, Douglas IS, Eisner M, Hite D, Holets S, Kallet RH, Liu KD, MacIntyre N, Moss M, Schoenfeld D, Steingrub J, Thompson BT. Randomized, placebo-controlled clinical trial of an aerosolized β_2 -agonist for treatment of acute lung injury. *Am J Respir Crit Care Med*. 2011 Sep 1;184(5):561-8.
 20. Calfee CS, Gallagher D, Abbott J, Thompson BT, Matthay MA; NHLBI ARDS Network. Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance. *Crit Care Med*. 2012 June 40: 1731-7, PMID: 22610178
 21. Kangelaris KN, Sapru A, Calfee CS, Liu KD, Pawlikowska L, Witte JS, Vittinghoff E, Zhuo H, Auerback AD, Ziv E, Matthay MA: National Heart, Lung, and Blood Institute ARDS Network. The association between a Darc gene polymorphism and clinical outcomes in African American patients with acute lung injury. *Chest* 141:1160-9, 2012 (epub 12-29-2011)
 22. Needham DM, Dinglas VD, Bienvenu OJ, Colantuoni E, Wozniak AW, Rice TW, Hopkins RO; NIH NHLBI ARDS Network. One year outcomes in patients with acute lung injury randomised to initial trophic or full enteral feeding: prospective follow-up of EDEN randomised trial. *BMJ*. 2013 Mar 19;346:f1532. PMID: 23512759

ABSTRACTS ACCEPTED FOR PRESENTATION

1. **Parsons PE**, Fowler AA, Hyers TM, Henson PM. Chemotactic activity in bronchoalveolar lavage fluid from patients with ARDS. *Am Rev Respir Dis* 125:51, 1982.
2. Martin RJ, Fernandez E, **Parsons PE**, Shoemaker S, Pluss W, Hudgel DW. The treatment of nocturnal asthma. *Am Rev Respir Dis* 127:109, 1983.
3. **Parsons PE**, Grunstein MM, Fernandez E. The effects of acute hypoxia and hypercapnia on pulmonary mechanics. *Am Rev Respir Dis* 129:A257, 1984.
4. **Parsons PE**, Cott GR, Mason RJ, Henson PM. Reversible oxidant "injury" of an

- epithelial cell monolayer. *Fed Am Soc Exp Biol* 43(3):777, 1984.
5. Sugahara K, Cott GR, **Parsons PE**, Henson PM, Mason RM. Activated neutrophils increase the permeability of alveolar epithelial monolayers: inhibition of α_1 -protease inhibitor and catalase. *Proc Int'l Cell Biol* pg 380, 1984.
 6. **Parsons PE**, Sugahara K, Mason RJ, Henson PM. The effect of neutrophil migration and prolonged neutrophil contact on epithelial permeability. *Proc Fed Am Soc Exp Biol* 44:1919, 1985.
 7. Fernandez E, **Parsons PE**, Grunstein MM. Assessment of inspiratory drive to breathe in normals and patients with chronic lung disease. *Am Rev Respir Dis*, 1985.
 8. **Parsons PE**, Tate RM, Worthen GS, Henson PM. Endotoxin and complement fragments (C5f) in plasma, but not elevated C5f levels alone, correlate with the development of ARDS. *Am Rev Respir Dis* 133:A277, 1986.
 9. Peterson VM, Moore EE, Jones TN, Rundus C, **Parsons PE**. Granulocyte stem cell response to major torso injury. *Society of University Surgeons*, 1987.
 10. **Parsons PE**, Giclas PC. The terminal complement complex (sC5b-9) is not specifically associated with the development of ARDS. *ARRD* 137(4):230, 1988.
 11. Whitfield JM, Kotzer AM, Gillespie M, **Parsons PE**. Aseptic spontaneous endotoxemia, respiratory failure and shock in the newborn. *The American Pediatric Society/The Society for Pediatric Research*, 1988.
 12. Moore FA, Haenel JB, Moore EE, McCroskey BL, **Parsons PE**. Safe intra-hospital transport of ventilated patients - the value of transcutaneous monitoring. *Society of Critical Care Medicine*, 1988.
 13. Moore FA, Moore EE, Haenel JB, Waring BJ, **Parsons PE**. Post-traumatic pulmonary pseudocyst in the adult: pathophysiology recognition and selective management. *Western Trauma Association*, 1989.
 14. **Parsons PE**, Worthen GS, Moore FA, Moore EE, Henson PM. Activity levels of circulating neutrophils in acute lung injury. *American Thoracic Society*, 1990.
 15. **Parsons PE**, Worthen GS, Moore FA, Moore EE, Henson PM. TNF concentrations do not parallel endotoxin levels in plasma from ARDS patients. *American Thoracic Society*, 1990.
 16. Moore FA, Poggetti RS, Moore EE, Renick M, Bennet L, **Parsons PE**, Peterson VM. Post-injury cytokine response - a selective depression in G-CSF. *American College of Surgeons*, 1990.
 17. Moore FA, Moore EE, Poggetti R, McAnena OJ, Abernathy CM, McCroskey BL, **Parsons PE**. Gut bacterial translocation via the portal vein: a clinical perspective in patients with major torso trauma. *American Association for the Surgery of Trauma* 1990.
 18. Poggetti RS, Moore FA, Banerjee A, Bansard DD, **Parsons PE**, Anderson BO, Moore EE. Gut and liver coordinated metabolic response following major trauma. *Association for Academic Surgery* 1990.
 19. McAnena O, Moore FA, Moore EE, Jones TN, **Parsons PE**. Selective uptake of glutamine in the gastrointestinal tract - confirmation in a human study. *European Surgical Research Society* 1990.
 20. Leff JA, **Parsons PE**, Day CE, Oppergard MA, Moore EE, Moore FA, Repine JE. Increased hydrogen peroxide scavenging and catalase activity in serum from septic patients who subsequently develop the Adult Respiratory Distress Syndrome (ARDS). *American Thoracic Society* 1991.
 21. **Parsons PE**, Moore FA, Moore EE, Giclas PC. Potential involvement of ceruloplasmin

- in the adult respiratory distress syndrome. American Thoracic Society 1991.
22. Linas SL, Whittenburg D, **Parsons PE**, Repine JE. Potential mechanism by which pre-renal azotemia predisposes to acute renal failure (ARF). American Society of Nephrology, 1991.
 23. Young SK, **Parsons PE**, Gillespie M, Moore EE, Moore FA, Worthen GS. Neutrophils, from patients with ARDS are retained in capillary sized pores. American Thoracic Society 1992.
 24. Moss M, Ackerson L, Gillespie MK, Moore FA, Moore EE, **Parsons PE**. Von Willebrand factor antigen levels do not predict the development of ARDS. American Thoracic Society, 1993.
 25. Linas SL, Whittenburg D, **Parsons PE**, Repine JE. Renal ischemia/reperfusion causes neutrophil (PMN) retention, activation, and worsening of renal injury. American Society of Nephrology, 1993.
 26. Moss, M, Gillespie MK, **Parsons PE**. Circulating neutrophil subpopulations identified by 31D8 are similar in chronic alcoholics and patients with Adult Respiratory Distress Syndrome. ALA/ATS International Conference, Boston, Mass. 1994.
 27. **Parsons PE**, Gillespie MMK, Moore EE, Moore FA, Moss M. The inflammatory modulator IL-10 is increased in patients at risk for and with ARDS. ALA/ATS International Conference, Seattle 1995.
 28. Khan TZ, Gillespie MMK, **Parsons PE**, Wagoner JS, Riches DWH, Accurso FJ. Airway inflammation in infants with cystic fibrosis can occur in the absence of detectable endotoxin in bronchoalveolar lavage fluid (BAL). ALA/ATS International Conference, Seattle, 1995.
 29. Moss M, Moore FA, Moore EE, **Parsons PE**. Patients who abuse alcohol have an increased incidence of Adult Respiratory Distress Syndrome. ALA/ATS International Conference, Seattle, 1995.
 30. Connelly KG, Moss M, **Parsons PE**, Moore EE, Moore FA, Giclas PC, Seligman PA, Repine JE. Serum ferritin levels as a predictor of the Acute Respiratory Distress Syndrome. ALA/ATS International Conference, New Orleans 1996.
 31. Moss M, Steinberg K, Guidot D, Duhon G, Treece P, Wolken R, Hudson L, **Parsons PE**. Diabetic patients with septic shock have a decreased incidence of the acute respiratory distress syndrome (ARDS) 155:A503, 1997.
 32. Wolken R, Goodman P, Knapp G, Hanley M, **Parsons PE**. Complications of mechanical ventilation (MV) have decreased in a city hospital MICU from 1990-1996. ALA/ATS International Conference, San Francisco, 1997.
 33. Goodman P, Wolken R, Heinig M, **Parsons PE**. Utility of portable cross table lateral CXR (LAT) for the evaluation of loculated pneumothorax (LPTX). ALA/ATS International Conference, San Francisco, 1997.
 34. Greene KE, Bucher-Bartelson BL, Akino Y, Kukuri N, King TE, Hunninghake GW, Newman LS, **Parsons PE**, Mason RJ. Serum SP-A and SP-D levels are elevated in patients with IPF. ALA/ATS International Conference, San Francisco, 1997.
 35. Greene KE, Ye S, Mason RJ, **Parsons PE**. Serum SP-A levels predict development of ARDS in at-risk patients. Thomas L. Petty Aspen Lung Conference, 1998. Chest 116: 90S-91S, 1999
 36. Moss M, Steinberg KP, Guidot DM, Duhon GF, Treece P, Wolken R, Hudson LD, **Parsons PE**. The effect of chronic alcohol abuse on the incidence of acute respiratory distress syndrome (ARDS) and the severity of non-pulmonary organ dysfunction

- syndrome in adults: An interim, prospective, and multi-variate analysis. Thomas L. Petty Aspen Lung Conference, Chest 116: 97S-98S
37. Parsons PE, for the NIH/NHIBI ARDS Network. Low tidal volume ventilation is routinely used in patient with early acute lung injury. ALA/ATS International Conference, San Diego, CA, 1999.
 38. Patterson RF, Ikle D, Linas SL, Parsons PE. Renal insufficiency is associated with a lower incidence of the acute respiratory distress syndrome in sepsis. ALA/ATS International Conference, San Diego CA, 1999.
 39. Parsons PE, for the NIH/NHIBI ARDS Network. The incidence of non-pulmonary organ failure is independent of PaO₂ / F_IO₂ ratio. ALA/ATS International Conference, San Diego CA, 1999.
 40. Eaton S, Burnham E, Steinberg KP, Hudson LD, Parsons PE, Moss M. Direct lung injury is associated with an increased incidence of the acute respiratory distress syndrome in septic patients. ALA/ATS International Conference, San Francisco, CA 2001.
 41. Ware LB, Eisner M, Thompson T, Parsons P, Matthay MA and the NIH ARDS Network. Von Willebrand Factor (VWF), a biochemical marker of endothelial injury, predicts outcome in ALI/ARDS and is not modulated by a protective ventilatory strategy. ALA/ATS International Conference, Atlanta, GA 2002
 42. Young M, Manning H, Wilson D, Mette S, Riker R, Bates J, Leiter J, Parsons P. Treating ALI/ARDS: Has new science changed practice? . ALA/ATS International Conference, Atlanta, GA 2002
 43. Burnham EL, Steinberg KP, Haber MJ, Hudson LD, Parsons PE, Moss M. Duration of mechanical ventilation and length of stay are increased in ARDS survivors with a history of alcohol abuse. ALA/ATS International Conference, Atlanta, GA 2002
 44. Ware LB, Ancukiewicz M, Parsons PE, Matthay MA. Prognostic Value of Plasma Protein C Levels in Patients with Acute Lung Injury. Am J Resp and Crit Care Med 167:A661, 2003
 45. Eisner MD, Parsons PE, Matthay MA, Ware L, Greene K. Prognostic value of plasma surfactant protein D level for clinical outcomes in patients with acute lung injury. Am J Resp and Crit Care Med 167:A179, 2003
 46. Young M, Bates J, Parsons P. Delays in transfer to the ICU: Do delays really matter? Am J Resp and Crit Care Med 169: A625, 2004
 47. Ware LB, Eisner MD, Wickersham N, Olman, MA, Thompson BT, Parsons P, Matthay MA. Plasminogen activator inhibitor-1 (PAI-1), a marker of impaired fibrinolysis, is associated with higher mortality in patients with ALI/ARDS. Am J Resp and Crit Care Med 169:A115, 2004
 48. Petty JM, Allen GB, Parsons PE, Suratt BT. The influence of mechanical ventilation on G-CSF release. Am J. Resp and Crit Care Med. 2:A317, 2005.
 49. Trimarchi T, Petty JM, Young MP, Allen GB, Parsons PE, Suratt BT and the NIH:NHLIBI ARDS Network. Plasma G-CSF levels are associated with mortality in ALI/ARDS. Am J. Resp and Crit Care Med. 3: A831, 2006
 50. Calfee CS, Eisner MD, Ware LB, Thompson BT, Parsons, PE, Wheeler, AP, Korpak A, Matthew MA. Trauma-associated acute lung injury differs clinically and biologically from non-trauma-associated acute lung injury. Am J Resp Crit Care Med 175:A757,2007
 51. Ware, LP, Billheimer D, Parsons, P, Thompson BT, Brower R, Standiford T, Martin, TR, Matthay MA. Combining clinical and biochemical indices improves prediction of outcomes in acute lung injury. Am J. Resp and Crit Care Med. 175:A966,2007

52. Stapleton RD, Dixon AE, Ware LB, **Parsons PE**, Suratt BT. Plasma IL-6 and IL-8 levels are lower in obese ARDS patients. *Am J Resp Crit Care Med* 177:A275, 2008
53. Calfee CS, Ware LB, Eisner ME, **Parsons PE**, Thompson BT, Wickersham N, Matthay MA, NHLBI ARDS Network Plasma receptor for advanced glycation end products (RAGE) predicts outcomes in patients with acute lung injury ventilated with traditional tidal volumes. *Am J Resp Crit Care Med* 177:A628, 2008
54. Calfee CS, Ware LB, Glidden DV, Eisner, MD, **Parsons PE**, Thompson BT, Matthay MA, Combining Multiple Biomarkers Improves Risk Prediction in Patients with ALI in Both Derivation and Replication Cohorts, *Am J Resp Crit Care Med* 179: A4626, 2009
55. Calfee, CS, Thompson BT, Parsons PE, Ware, LP, Matthay MA, Wong HR and the NIH NHLBI ARDS Network. *Am J. Respiratory Critical Care Medicine* 181: A1652, 2010

SELECTED INVITED PRESENTATIONS:

1. Detection of Endotoxin in Patients with ARDS. Workshop on Non-Culture Diagnosis of Pneumonia in Acute Lung Injury. NHLBI, NIH, 1987.
2. Endotoxin in ARDS. International Conference: American Thoracic Society and American Lung Association, 1991.
3. Clinical Profiles in Patients at Risk for ARDS. Contemporary Clinical Trials in Acute Respiratory Distress Syndrome, 1991.
4. ARDS Research Needs and Opportunities Related to Respiratory Health in Women. NHLBI, NIH, 1992.
5. Session Chair - Inflammation in Cardiovascular Lung, and Blood Diseases. NHLBI, 1993.
6. Co-Chair and Organizer: Thomas L. Petty, 36th Aspen Lung Conference: Acute Lung Injury, 1993.
7. New Modes of Ventilation in ARDS; Pathogenesis of ARDS; Asthma; Advances in Medicine Critica. Quito, Ecuador, 1993.
8. Clinical Year-In-Review, ARDS. American Thoracic Society, 1995.
9. Juror, European Consensus Conference in Intensive Care Medicine: Tissue Hypoxia, 1995.
10. Complement, Endotoxin and the Lung. Brussels Round Table Conference on Acute Lung Injury, 1997.
11. Validating Biomarkers and Ascertaining their Relationship to Clinical Endpoints, NIH/FDA Conference, Biomarkers and Surrogate Endpoints, 1999.
12. Targets for Genetic Studies in ARDS; ATS Conference: Genetics and the Inflammatory Response, 1999.
13. New Concepts in Lung Injury and Repair in the Critically Ill Annual meeting of the American Society of Anesthesiologists, 1999.
14. Epidemiology, Pathophysiology and Natural History of ALI/ARDS. Kjeldgaard Day Symposium, 2000.
15. Risk Factors and Mechanisms; NHLBI Working Group: Research Opportunities in the Clinical Epidemiology of Lung Injury and Critical Illness, 2000.
16. Translational Approaches to ALI Roundtable; NHLBI Working Group: Future Research Directions in Acute Lung Injury, 2002
17. Clinical Year-In-Review, ARDS. American Thoracic Society, 2003

18. ICU Issues: Withdrawal of Treatment, Not Care. End-of-Life Conference 2003
19. Ventilation Strategies in ARDS. Northern New England Critical Care Conference, 2003
20. Evidence-Based Management of Acute Respiratory Distress Syndrome in 2003. ACCP New England States Chapter, 2003
21. ARDS: Old and New. Northern New England Critical Care Conference, 2004
22. The Holy Grail of the Paper Trail. 1st Conference and Workshop for Pulmonary & Critical Care Fellowship Program Directors. 2005
23. ARDS/ALI Update, Northern New England Critical Care Conference 2005
24. ATS Fellows Center: How to Say No and Manage Your Time Effectively, 2010
25. Society of Critical Care Medicine Congress 2012: Plenary Speaker
26. American College of Physicians: Update in Critical Care, 2012
27. Pittsburgh International Lung Conference on ARDS 2012
28. University of Colorado Department of Medicine Robert W. Schrier Honorary Event 2012
29. University of Washington: John Butler Lecture, 2013